Fracture Incidence, Quality of Life, and Back Pain during 18-Months Treatment with Teriparatide in Greek Postmenopausal Women with Osteoporosis: Results from the European Forsteo Observational Study

Table 1

Osteoporosis medications (other than teriparatide) prior and during the course of the study.

Medication	Past use at baseline; (𝑁=301)	Ongoing at baseline; (𝑁=301)	3 months; (𝑁=297)^a	6 months; (𝑁=282)^a	12 months; (𝑁=280)^a	18 months; (𝑁=278)^a
Any medication	83.7%	74.0%	78.6%	79.0%	81.4%	76.9%
Any antiresorptives	81.7%	34.4%	6.8%	7.1%	7.9%	9.4%
Any bisphosphonates	38.0%	12.0%	0.7%	0.7%	1.8%	2.5%
Estrogen/progestin therapy	1.3%	0.0%	0.0%	0.0%	0.0%	0.0%
Estrogen therapy	1.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Raloxifene	7.0%	1.0%	1.0%	0.7%	0.4%	0.4%
Calcitonin	65.0%	21.4%	6.1%	6.0%	5.7%	6.5%
Calcium	68.0%	67.7%	75.6%	78.6%	81.1%	75.5%
Vitamin D	53.7%	62.5%	72.2%	74.0%	75.0%	70.8%
None reported	16.3%	26.0%	21.4%	21.0%	18.6%	23.1%

^aStarted since previous observation.